ECO 2026: Wegovy HD shows nearly 28% weight loss in early responders

At the European Congress on Obesity (ECO) on May 12, 2026, Novo Nordisk presented new analyses of its STEP UP research program showing that semaglutide 7.2 mg — the injectable dose sold as Wegovy HD — produced weight loss of nearly 28% among participants who responded early in treatment ^[1]. The finding comes from an exploratory subgroup analysis, not a measure of the average result across all trial participants ^[1].

Wegovy HD is the newest and highest dose of the Wegovy injection line. It received FDA approval on March 19, 2026, as the version of Wegovy delivering the highest weight loss to date for the injectable form ^[1]. That approval followed earlier data, released June 21, 2025, showing the higher dose produced an average weight loss of about 21% in people with obesity, with roughly a third of participants losing 25% or more ^[1]. The nearly 28% figure presented at ECO applies specifically to people identified as early responders, a smaller group within the larger trial population ^[1].

Novo Nordisk also presented related early-responder data at the same conference for its oral semaglutide product. On May 13, 2026, the company reported that the Wegovy pill delivered 21.6% weight loss in early responders, along with improvements in mobility ^[1]. Together, the two presentations suggest the company is emphasizing how early weight-loss trajectory may relate to eventual results, across both the injectable and oral versions of semaglutide ^[1].

Wegovy, the brand name for semaglutide, is a GLP-1 receptor agonist approved for weight management, reduction of cardiovascular risk in adults with established heart disease and obesity or overweight, and treatment of MASH (metabolic dysfunction-associated steatohepatitis) with moderate to advanced liver fibrosis ^[1]. It works partly by activating GLP-1 receptors in brain regions involved in appetite regulation, which is thought to reduce caloric intake ^[1]. The injection is available in doses up to 7.2 mg, and the tablet form up to 25 mg ^[1]. The drug carries a boxed warning for thyroid C-cell tumors, and common side effects include nausea, diarrhea, vomiting, constipation, and abdominal pain, among others ^[1].

Why it matters for patients

The nearly 28% figure is notably higher than the roughly 21% average weight loss reported in the broader higher-dose Wegovy study from 2025 ^[1]. That gap matters because it reflects a selected group of people who happened to respond quickly, not what a typical patient starting Wegovy HD should expect. Novo Nordisk's own approval history describes this and the related oral-pill analysis as exploratory, meaning they describe a subgroup rather than predict outcomes for everyone ^[1].

Cost and access remain separate but relevant issues for patients weighing these medications. Novo Nordisk has taken several steps affecting affordability, including a list price reduction for Wegovy, Ozempic, and Rybelsus announced February 24, 2026, and a multi-month subscription program launched March 31, 2026, offering savings of up to $1,200 per year ^[1]. Neither of these programs is tied specifically to the new ECO data, but they shape what patients might pay if pursuing higher-dose or newer formulations.

What happens next

Novo Nordisk continued presenting additional analyses from its semaglutide research programs at ECO 2026, including the May 13, 2026 data on the oral Wegovy pill in early responders ^[1]. It is not yet known when full peer-reviewed results from the STEP UP program, including longer-term outcomes for early versus later responders, will be published. Patients and clinicians will likely need to wait for that fuller dataset to understand how meaningful early response is as a predictor of total weight loss over time.